诊断后使用抗高血压药物与卵巢癌死亡风险
该队列研究利用SEER-Medicare数据纳入2195例66岁以上、2007-2012年诊断且生存至少12个月的卵巢癌女性,评估诊断后1年内使用噻嗪类利尿剂、ACEI、β受体阻滞剂和钙通道阻滞剂与卵巢癌特异性生存的关联。结果显示使用ACEI、噻嗪类利尿剂或非选择性β受体阻滞剂者卵巢癌特异性死亡风险较低,但作者指出疾病严重程度残余混杂可能,需谨慎解读。
要点
- 使用ACEI者卵巢癌特异性死亡风险较低(aHR 0.76,95%CI 0.63-0.92)。
- 使用噻嗪类利尿剂者风险较低(aHR 0.82,95%CI 0.68-0.99)。
- 使用非选择性β受体阻滞剂者风险较低(aHR 0.60,95%CI 0.43-0.83),选择性β受体阻滞剂或钙通道阻滞剂未见此关联。
核心结论
- 诊断后1年内使用ACEI、噻嗪类利尿剂或非选择性β受体阻滞剂的卵巢癌女性,此后死于该病的风险相对较低。
- 作者指出疾病严重程度残余混杂可能,需谨慎解读。
研究设计与样本
- 队列研究,使用SEER-Medicare数据,纳入2195例66岁及以上、2007-2012年诊断且生存至少12个月的卵巢癌女性。
- 抗高血压药物使用定义为诊断后1年内配药≥2次,从诊断后1年开始随访至2013年底评估卵巢癌特异性死亡。
- 采用Cox比例风险模型比较特定抗高血压药物类别使用者与非抗高血压药物使用者。
主要发现
- 718例(33%)使用噻嗪类利尿剂,690例(31%)使用ACEI,521例(24%)使用β受体阻滞剂,154例(7%)使用钙通道阻滞剂,48%使用一种以上类别。
- 使用ACEI者卵巢癌特异性死亡风险较低(aHR 0.76,95%CI 0.63-0.92)。
- 使用噻嗪类利尿剂者风险较低(aHR 0.82,95%CI 0.68-0.99)。
- 使用非选择性β受体阻滞剂者风险较低(aHR 0.60,95%CI 0.43-0.83)。
- 使用选择性β受体阻滞剂或钙通道阻滞剂者未见此类关联。
临床怎么用
- 作者结论指出,观察到的关联可能受疾病严重程度残余混杂影响,需谨慎解读。
局限性
- 作者指出疾病严重程度残余混杂可能,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine associations between post-diagnosis use of antihypertensive (AH) medications including thiazide diuretics (TDs), angiotensin converting enzyme inhibitors (ACEIs), beta blockers (BBs) [both non-selective (NSBBs) and selective (SBBs)] and calcium channel blockers (CCBs) and ovarian cancer-specific survival. METHODS: This cohort study used SEER-Medicare data on 2195 women 66+ years of age who were diagnosed with ovarian cancer during 2007-2012 and who survived for at least 12 months. Use of an AH class was defined as two or more fills during the year after diagnosis. Ovarian cancer-specific death was assessed starting one year after diagnosis and continued through the end of 2013. Associations between AH use and ovarian cancer-specific mortality were assessed using Cox proportional hazard models, comparing users of a given class of AH to non-AH users. RESULTS: Overall, 718 (33%), 690 (31%), 521 (24%), 154 (7%) of women used a TD, ACEI, BB, or CCB, respectively, with some women (48%) using more than one class of drug. Ovarian cancer-specific mortality was found to be lower among women who used an ACEI (adjusted hazard ratio [aHR] 0.76, 95% confidence interval [CI] 0.63-0.92), a TD (aHR 0.82, 95%CI 0.68-0.99), or a NSBB (aHR 0.60, 95%CI 0.43-0.83), but no such association was seen in women who took a SBB or CCB. CONCLUSION: We observed that women who took certain forms of an AH medication during the year following a diagnosis of ovarian cancer were thereafter at a relatively reduced risk of dying from their disease. However, the potential for residual confounding by disease severity argues for a cautious interpretation.
引用
- Harding BN, Delaney JA, Urban RR, et al. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 2019. PMID: 31178150. doi:10.1016/j.ygyno.2019.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。